 | • レポートコード：MRC-IM30206 • 出版社/出版日：IMARC / 2022年10月 • レポート形態：英文、PDF、145ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥359,856 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥647,856 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| IMARC社の調査レポートによると、世界の多発性硬化症治療市場規模は2021年に245億ドルに達しました。今後、2027年には323億ドルになり、2022年から2022年の間に年平均4.61％成長すると予測しています。本調査レポートでは、多発性硬化症治療の世界市場について調査・分析を行い、序論、調査範囲・手法、エグゼクティブサマリー、イントロダクション、薬剤別（免疫調節剤、免疫抑制剤）分析、薬物種類別（生物製剤、低分子医薬品）分析、投与経路別（経口、注射、静脈内）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などを掲載しています。なお、企業情報には、Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.などが含まれています。 ・序論 ・調査範囲・手法 ・エグゼクティブサマリー ・イントロダクション ・世界の多発性硬化症治療市場規模：薬剤別 - 免疫調節剤の市場規模 - 免疫抑制剤の市場規模 ・世界の多発性硬化症治療市場規模：薬物種類別 - 生物製剤の市場規模 - 低分子医薬品の市場規模 ・世界の多発性硬化症治療市場規模：投与経路別 - 経口治療薬の市場規模 - 注射治療の市場規模 - 静脈内治療の市場規模 ・世界の多発性硬化症治療市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の多発性硬化症治療市場規模：地域別 - 北米の多発性硬化症治療市場規模 - アジアの多発性硬化症治療市場規模 - 欧州の多発性硬化症治療市場規模 - 中南米の多発性硬化症治療市場規模 - 中東・アフリカの多発性硬化症治療市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global multiple sclerosis therapies market size reached US$ 24.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 32.3 Billion by 2027, exhibiting a growth rate (CAGR) of 4.61% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.
The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug, drug type, route of administration and distribution channel.
Breakup by Drug:
Immunomodulators
Copaxone
Avonex/Plegridy
Gilneya
Tysabri
Betaseron/Extavia
Tecifidera
Rebif
Ampyra
Immunosuppressants
Aubagio
Lemtrada
Ocrelizumab
Zinbryta
Breakup by Drug Type:
Biologic Drugs
Small Molecule Drugs
Breakup by Route of Administration:
Oral
Injectable
Intravenous
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
What are the key regional markets?
What is the breakup of the market based on the drug?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global multiple sclerosis therapies market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Multiple Sclerosis Therapies Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug
6.1 Immunomodulators
6.1.1 Market Trends
6.1.2 Major Types
6.1.2.1 Copaxone
6.1.2.2 Avonex/Plegridy
6.1.2.3 Gilneya
6.1.2.4 Tysabri
6.1.2.5 Betaseron/Extavia
6.1.2.6 Tecifidera
6.1.2.7 Rebif
6.1.2.8 Ampyra
6.1.3 Market Forecast
6.2 Immunosuppressants
6.2.1 Market Trends
6.2.2 Major Types
6.2.2.1 Aubagio
6.2.2.2 Lemtrada
6.2.2.3 Ocrelizumab
6.2.2.4 Zinbryta
6.2.3 Market Forecast
7 Market Breakup by Drug Type
7.1 Biologic Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Small Molecule Drugs
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Oral
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Injectable
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Intravenous
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Abbvie Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Bayer Aktiengesellschaft
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Biogen Inc.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Bristol-Myers Squibb Company
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 SWOT Analysis
15.3.6 GlaxoSmithKline Plc
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Merck & Co. Inc.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Novartis AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Sanofi S.A.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Teva Pharmaceutical Industries Ltd.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2021
Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2021
Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2021
Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2021
Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter’s Five Forces Analysis
• 日本語訳：多発性硬化症治療の世界市場：動向・シェア・規模・予測
• レポートコード：MRC-IM30206 ▷ お問い合わせ（見積依頼・ご注文・質問）